G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer, administered prior to specific platinum/etoposide- or topotecan-containing regimens. The company is also actively progressing several investigational compounds. Trilaciclib, a CDK4/6 inhibitor, is currently undergoing extensive clinical evaluation, including Phase III studies for first-line colorectal cancer and first-line triple-negative breast cancer. Additionally, it is in Phase II trials for initial bladder cancer treatment, in combination with an antibody-drug conjugate, and as a neoadjuvant therapy for breast cancer. Their development pipeline further includes lerociclib, an oral CDK4/6 inhibitor intended for multiple oncological applications, and rintodestrant, an orally administered selective estrogen receptor degrader, which is in Phase IIa clinical trials for estrogen receptor-positive, HER2-negative breast cancer. G1 Therapeutics has forged several strategic licensing agreements. They have partnered with EQRx, Inc. and Genor Biopharma Co. Inc. for the oral formulation of lerociclib, encompassing all human indications. A separate collaboration with Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. covers the parenteral development and market introduction of trilaciclib for any human indication. Furthermore, the company works with ARC Therapeutics on a CDK2 inhibitor, designated for both human and veterinary uses. Established in 2008, G1 Therapeutics, Inc. is headquartered in Research Triangle Park, North Carolina.
